Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Looks to Log Over 800 Billion Yen in FY2020, Lenvima as Key Growth Engine
March 4, 2016
- Teva Pharma Japan Voluntarily Recalling 7 Products
March 3, 2016
- Public Knowledge-Based Application Filed for Xeloda as Adjuvant Chemotherapy for Rectal Cancer: Chugai
March 3, 2016
- Pfizer Japan Chief Frets Possible Decline in Foreign Investments amid Anti-Innovation Drug Policies
March 3, 2016
- Pfizer’s Japan Sales Tick Up 2% in FY2015
March 3, 2016
- Takeda and Mizuho Medy Tie Up for Marketing of OTC Pregnancy Test Kit, Ovulation Predictor Kit
March 3, 2016
- Eisai Board OKs Hajime Shimizu as 1st President of EA Pharma
March 2, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Drug Wholesalers’ Inventory Margins Likely to Diminish for FY2016 Price Revision
March 1, 2016
- MSD Seeks Lung Cancer Indication for Pembrolizumab in Japan
March 1, 2016
- Shionogi Links Arms with Roche on Sakigake-Designated Anti-Flu Drug
March 1, 2016
- New Presidents Announced for Alfresa, Suzuken, Fuji Pharma
February 29, 2016
- Takeda Gets Approval for Blister Packs Containing Takecab for H. pylori Eradication
February 29, 2016
- Novartis Seeks Japan Approval of Malaria Drug
February 29, 2016
- GSK, Daiichi Sankyo Voluntarily Recalling Zyrtec Tablets 5
February 29, 2016
- PCSK9 Inhibitor Repatha Expected to Debut this Spring, with Competing Products to Follow
February 29, 2016
- Daiichi Sankyo Launches Japan Clinical Trial on DMD Nucleic Acid Therapy
February 26, 2016
- Sanofi Seeks to Change Lyxumia Indication to Type 2 Diabetes without Strings
February 26, 2016
- Daiichi Sankyo to Revamp Organization to Boost Cancer R&D
February 26, 2016
- Torii to Expand Sales Force to 570 by FY2018; Will Actively Seek Acquisitions, Alliances
February 26, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…